UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

June 19, 2013

________________

NOVO NORDISK A/S(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]           Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]            No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 

Federal Circuit Court rules on patent litigation involving 

Prandin®(repaglinide) 

Bagsværd, Denmark & Plainsboro, NJ 18  June 2013 – Today, the U.S. Court of Appeals for the Federal Circuit partially affirmed a 2011 District Court decision, with a2-1 ruling that a claim in a Novo Nordisk patentrelated to the use of repaglinide in combination with metformin forthe treatment of type 2 diabetes wasinvalid. This decision favors approval and launch of ageneric repaglinide product. 

The Federal Circuit  also reversed, with a unanimous 3-0 ruling, the  District Court decision that NovoNordisk had committed inequitable conduct during the time the company attempted toacquire the patent. 

Novo Nordisk continues to believe in the validity ofthe patent and is reviewing theruling. Novo Nordisk expectsto provide an update on the case in connection  with the announcement of  the financial results for the first six months of 2013on 8August 2013. 

Novo Nordisk markets repaglinide under the trade name Prandin ®anda fixed-dose repaglinide/metformin tablet under the tradename PrandiMet ®in the US. In2012, sales of Prandin ®andPrandiMet ®in the US amounted to 1.2billion Danish kroner (approximately 200 million USD).

Novo Nordiskis a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy andhormone replacement therapy. Headquartered inDenmark, Novo Nordisk  employs approximately 35,000 employees in 75 countries, and markets its products inmore than 180 countries. Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock  Exchange (NVO). For more information, visit novonordisk.com. 

Further information
Media:
Mike Rulis	+45 3079 3573	mike@novonordisk.com
Ken Inchausti (US)	+1 609 240 2919	kiau@novonordisk.com
Investors:
Kasper Roseeuw Poulsen	+45 4442 4303	krop@novonordisk.com
Frank Daniel Mersebach	+45 4442 0604	fdni@novonordisk.com
Lars Borup Jacobsen	+45 3075 3479	lbpj@novonordisk.com
Jannick Lindegaard (US)	+1 609 786 4575	jlis@novonordisk.com

Novo Nordisk A/S	Novo Allé	Telephone:	CVR no:
Investor Relations	2880 Bagsværd	+45 4444 8888	24 25 67 90
	Denmark	Internet:
		www.novonordisk.com
		Company announcement No 45 / 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: June 19, 2013 NOVO NORDISK A/S Lars Rebien Sørensen, President and Chief Executive Officer